Metformin reduces thyroid cancer risk in taiwanese patients with type 2 diabetes

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TICLOPIDINE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL PARAMETERS; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; TAIWANESE; THYROID CANCER; TREATMENT DURATION; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLICATION; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; INCIDENCE; RISK; TAIWAN; THYROID NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; TAIWAN; THYROID NEOPLASMS;

EID: 84907858388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109852     Document Type: Article

References (43)

1. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, et al. (2012) Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012: 789174.
2. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47: 87-95.
3. Tseng CH (2011) Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut 60: 774-779.
4. Tseng CH, Chong CK, Tseng CP, Chan TT (2009) Age-related risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in Taiwan. Ann Med 41: 371-379.
5. Tseng CH (2011) Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan. Diabetologia 54: 2009-2015.
6. Tseng CH (2012) Diabetes and non-Hodgkin's lymphoma: Analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan. Ann Oncol 23: 153-158.
7. Tseng CH (2012) Diabetes, insulin use, and non-Hodgkin lymphoma mortality in Taiwan. Metabolism 61: 1003-1009.
8. Tseng CH (2013) New-onset diabetes with a history of dyslipidemia predicts pancreatic cancer. Pancreas 42: 42-48.
9. Dong X, Li Y, Tang H, Chang P, Hess KR, et al. (2012) Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 36: 206-211.
10. Gursoy A (2010) Rising thyroid cancer incidence in the world might be related to insulin resistance. Med Hypotheses 74: 35-36.
11. Tseng CH (2012) Thyroid cancer risk is not increased in diabetic patients. PLoS One 7: e53096.
12. Tseng CH (2012) Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J Endocrinol 167: 409-416.
13. Tseng CH (2013) Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 13: 7.
14. Tseng CH (2014) Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes. Acta Diabetol 51: 295-303.
15. Tseng CH (2014) Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat 145: 785-790.
16. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, et al. (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 8: e71583.
17. Tseng CH (2013) Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan. Acta Diabetol 50: 879-886.
18. Tseng CH (2013) Type 2 diabetes, smoking, insulin use and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan. Hepatol Int 7: 693-702.
19. Tseng CH (2013) Insulin use and smoking jointiy increase the risk of bladder cancer mortality in patients with type 2 diabetes. Clin Genitourin Cancer 11: 508-514.
20. Tseng CH (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35: 278-280.
21. Tseng CH, Tseng FH (2012) Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 30: 368-402.
22. Tseng CH (2014) A review on thiazolidinediones and bladder cancer in human studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32: 1-45.
23. Tseng CH (2013) Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol 37: 385-389.
24. Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, et al. (2012) Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer 19: 447-456.
25. Chen G, Xu S, Renko K, Derwahl M (2012) Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 97: E510-520.
26. Vigersky RA, Filmore-Nassar A, Glass AR (2006) Thyrotropin suppression by metformin. J Clin Endocrinol Metab 91: 225-227.
27. DiezJJ, Iglesias P (2013) Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol (Oxf) 78: 505-511.
28. Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H (2011) Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 9: 69-75.
29. Rizos CV, Elisaf MS (2013) Metformin and cancer. Eur J Pharmacol 705: 96-108.
30. Tseng CH (2014) Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes. Eur J Clin Invest 44: 736-742.
31. Kourelis TV, Siegel RD (2012) Metformin and cancer: new applications for an old drug. Med Oncol 29: 1314-1327.
32. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, et al. (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31: 3069-3075.
33. Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH (2006) Polypharmacy with oral antidiabetic agents: an indicator of poor glycemie control. Am J Manag Care 12: 435-440.
34. Aijada A, Mousa SA (2012) Metformin and neoplasia: Implications and indications. Pharmacol Ther 133: 108-115.
35. Ittermann T, Markus MR, Schipf S, Derwahl M, Meisinger C, et al. (2013) Metformin inhibits goitrogenous effects of type 2 diabetes. Eur J Endocrinol 169: 9-15.
36. Cappelli C, Rotondi M, Pirola I, Agosti B, Formenti A, et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 167: 261-265.
37. Nar A, Gedik O (2009) The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46: 113-118.
38. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, et al. (2013) Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab 98: 3269-3279.
39. Malaguarnera R, Frasca F, Garozzo A, Gianì F, Pandini G, et al. (2011) Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab 96: 766-774.
40. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, et al. (2013) Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 12: 145-156.
41. Würth R, Barbieri F, Florio T (2014) New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int 2014: 126586.
42. Tseng CH (2013) Diabetes and thyroid cancer mortality: a 12-year prospective follow-up of Taiwanese. Eur J Clin Invest 43: 595-601.
43. Shih SR, Chiu WY, Chang TC, Tseng CH (2012) Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res 2012: 578285.